非小细胞肺癌患者血清p16基因启动子甲基化分析

Analysis of promoter hypermethylation of p16 gene in sera from non-small cell lung cancer patients

目的:分析非小细胞肺癌(NSCLC)患者血清中p16基因启动子区域甲基化状况及其临床意义。方法:运用甲基化特异性PCR技术,检测65例NSCLC患者血清p16基因启动子区域甲基化情况,并分析与临床病理资料的关系。结果:NSCLC患者血清p16基因甲基化检出率为43.1%(28/65),而正常对照组和良性肺部疾病组未检出;p16基因甲基化检出率与NSCLC病理类型、分期及转移状态无明显关系。结论:p16基因启动子区域甲基化是NSCLC早期辅助诊断的分子标记物之一。

Objective:To analyze the aberrant methylation of p16 gene in sera from non-small cell lung cancer patients and to evaluate the clinical significance. Methods:A methylation-specific PCR was performed for the detection of promoter hypermethylation of p16 gene in blood DNA from 65 cases of NSCLC patients,and to analyze the relation of the aberrant methylation of p16 gene and the clinical pathological data. Results:The incidence of the hypermethylation of p16 promoter in sera from 65 cases of NSCLC patients was 43.1%(28/65),whereas no methylated p16 gene promoter was found in sera from benign lung diseases and normal control. Methylated p16 gene promoter in serum did not strongly correlated with the pathological classification, stage ,metastasis and differentiation in NSCLC. Conclusion:Detection of the aberrant methylation of p16 gene in blood DNA from NSCLC patients might offer an effective means for the earlier auxillary diagnosis of the malignancy.